Abstract
Primary aldosteronism (PA) is the most common cause of secondary hypertension. It predisposes to adverse outcomes such as nephrotoxicity and cardiovascular damage, which are mediated by direct harm from hypertension to the target organs. Accurate subtype diagnosis and localization are crucial elements in choosing the type of treatment for PA in clinical practice since the dominant side of aldosterone secretion in PA affects subsequent treatment options. The gold standard for diagnosing PA subtypes, adrenal venous sampling (AVS), requires specialized expertise, the invasive nature of the procedure and high costs, all of which delay the effective treatment of PA. Nuclide molecular imaging is non-invasive and has wider applications in the diagnosis and treatment of PA. This review aims to provide a summary of the application of radionuclide imaging in the diagnosis, treatment management and prognostic assessment of PA.
Similar content being viewed by others
Data availability
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
Turcu AF, Yang J, Vaidya A. Primary aldosteronism—a multidimensional syndrome. Nat Rev Endocrinol. 2022;18:665–82.
Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–20.
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–916.
Rossi GP, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, et al. Clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling. Hypertens Dallas Tex. 1979;2019(74):800–8.
Rossi GP, Auchus RJ, Brown M, Lenders JWM, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertens Dallas Tex. 1979;2014(63):151–60.
Rossi GP, Maiolino G, Seccia TM. Adrenal venous sampling: where do we stand? Endocrinol Metab Clin North Am. 2019;48:843–58.
Ladurner R, Sommerey S, Buechner S, Dietz A, Degenhart C, Hallfeldt K, et al. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur J Clin Invest. 2017;47:372–7.
Aono D, Kometani M, Karashima S, Usukura M, Gondo Y, Hashimoto A, et al. Primary aldosteronism subtype discordance between computed tomography and adrenal venous sampling. Hypertens Res. 2019;42:1942–50.
Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136:1227–35.
Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrinol. 2002;147:13–28.
Sarkar SD, Beierwaltes H, Ice RD, Basmadjian GP, Hetzel KR, Kennedy WP, et al. A new and superior adrenal scanning agent, NP-59. J Nucl Med Off Publ Soc Nucl Med. 1975;16:1038–42.
Wu M-H, Liu F-H, Lin K-J, Sun J-H, Chen S-T. Diagnostic value of adrenal iodine-131 6-β-iodomethyl-19-norcholesterol scintigraphy for primary aldosteronism: a retrospective study at a medical center in North Taiwan. Nucl Med Commun. 2019;40:568–75.
the TAIPAI Study Group, Lu C-C, Wu V-C, Wu K-D, Liu K-L, Lin W-C, et al. Prognostic value of semiquantification NP-59 SPECT/CT in primary aldosteronism patients after adrenalectomy. Eur J Nucl Med Mol Imaging. 2014;41:1375–84.
Yen R-F, Wu V-C, Liu K-L, Cheng M-F, Wu Y-W, Chueh S-C, et al. 131I–6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med Off Publ Soc Nucl Med. 2009;50:1631–7.
Lenzini L, Rossitto G, Maiolino G, Letizia C, Funder JW, Rossi GP. A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma. J Clin Endocrinol Metab. 2015;100:E1089–95.
Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768–72.
Arnesen T, Glomnes N, Strømsøy S, Knappskog S, Heie A, Akslen LA, et al. Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway. Langenbecks Arch Surg. 2013;398:869–74.
Scholl UI, Lifton RP. New insights into aldosterone-producing adenomas and hereditary aldosteronism: mutations in the K+ channel KCNJ5. Curr Opin Nephrol Hypertens. 2013;22:141–7.
Ip JCY, Pang TCY, Pon CK, Zhao JT, Sywak MS, Gill AJ, et al. Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism. ANZ J Surg. 2015;85:279–83.
Vilela LAP, Rassi-Cruz M, Guimaraes AG, Moises CCS, Freitas TC, Alencar NP, et al. KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2019;104:4695–702.
Lu C-C, Yen R-F, Peng K-Y, Huang J-Y, Wu K-D, Chueh JS, et al. NP-59 adrenal scintigraphy as an imaging biomarker to predict KCNJ5 mutation in primary aldosteronism patients. Front Endocrinol. 2021;12: 644927.
Counsell RE, Ranade VV, Blair RJ, Beierwaltes WH, Weinhold PA. Tumor localizing agents. IX. Radioiodinated cholesterol. Steroids. 1970;16:317–28.
Kobayashi T, Maeda M, Haradahira T, Kojima M. Fluoro norcholesterol analogues. Synthesis of 6 β-(2’-fluoro) ethyl-19-norcholest-5(10)-en-3 β-ol. Steroids. 1982;39:585–93.
Winton WP, Brooks AF, Wong KK, Scott PJH, Viglianti BL. Synthesis of 6-(Fluoromethyl)-19-norcholest-5(10)-en-3-ol, a fluorinated analogue of NP-59, using the mild fluorinating reagent, TBAF(Pinacol)2. SynOpen. 2019;03:55–8.
Brooks AF, Winton WP, Stauff J, Arteaga J, Henderson B, Niedbala J, et al. Development of fluorinated NP-59: a revival of cholesterol use imaging with PET. J Nucl Med Off Publ Soc Nucl Med. 2022;63:1949–55.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med Off Publ Soc Nucl Med. 2005;46:1023–7.
Nakamura Y, Maekawa T, Felizola SJA, Satoh F, Qi X, Velarde-Miranda C, et al. Adrenal CYP11B1/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies. Mol Cell Endocrinol. 2014;392:73–9.
Bergström M, Bonasera TA, Lu L, Bergström E, Backlin C, Juhlin C, et al. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med Off Publ Soc Nucl Med. 1998;39:982–9.
Mitterhauser M, Wadsak W, Wabnegger L, Sieghart W, Viernstein H, Kletter K, et al. In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats. Eur J Nucl Med Mol Imaging. 2003;30:1398–401.
Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, et al. [123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab. 2008;93:2358–65.
Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerström G, et al. PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer 11C-metomidate. J Nucl Med Off Publ Soc Nucl Med. 2000;41:275–82.
Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, et al. Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11β-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging. 2004;31:1224–30.
Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Långsjö J, et al. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med Off Publ Soc Nucl Med. 2004;45:972–9.
Hennings J, Lindhe O, Bergström M, Långström B, Sundin A, Hellman P. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab. 2006;91:1410–4.
Soinio M, Luukkonen A-K, Seppänen M, Kemppainen J, Seppänen J, Pienimäki J-P, et al. Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. Eur J Endocrinol. 2020;183:539–50.
Crimì F, Spimpolo A, Cecchin D, Rossi GP. Functional imaging by 11C-metomidate PET: a really useless technique for primary aldosteronism subtyping? Eur J Endocrinol. 2021;184:L9-10.
Newton MA, Laragh JH. Effects of glucocorticoid administration on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism. J Clin Endocrinol Metab. 1968;28:1014–22.
Hennings J, Sundin A, Hägg A, Hellman P. 11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbecks Arch Surg. 2010;395:963–7.
Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of 11 C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s Adenomas. J Clin Endocrinol Metab. 2012;97:100–9.
Puar TH, Khoo CM, Tan CJ, Tong AKT, Tan MCS, Teo AED, et al. 11C-Metomidate PET-CT versus adrenal vein sampling to subtype primary aldosteronism: a prospective clinical trial. J Hypertens. 2022;40:1179–88.
Lu C-C, Chen C-J, Peng K-Y, Chueh JS, Chang C-C, Yen R-F, et al. Predicting treatment response in primary aldosteronism using 11C-metomidate positron emission tomography. Clin Nucl Med. 2022;47:936–42.
Wu X, Senanayake R, Goodchild E, Bashari WA, Salsbury J, Cabrera CP, et al. [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nat Med. 2023;29:190–202.
Inoue K, Yamazaki Y, Kitamoto T, Hirose R, Saito J, Omura M, et al. Aldosterone suppression by dexamethasone in patients with KCNJ5-mutated aldosterone-producing adenoma. J Clin Endocrinol Metab. 2018;103:3477–85.
Sonoyama T, Sone M, Tamura N, Honda K, Taura D, Kojima K, et al. Role of endogenous ACTH on circadian aldosterone rhythm in patients with primary aldosteronism. Endocr Connect. 2014;3:173–9.
Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, Verburg FA, et al. Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. J Clin Endocrinol Metab. 2013;98:1508–18.
Heinze B, Schirbel A, Nannen L, Michelmann D, Hartrampf PE, Bluemel C, et al. Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. Eur J Nucl Med Mol Imaging. 2021;49:301–10.
Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10:1–16.
Wadsak W, Mitterhauser M, Rendl G, Schuetz M, Mien LK, Ettlinger DE, et al. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging. 2006;33:669–72.
Abe T, Naruse M, Young WF, Kobashi N, Doi Y, Izawa A, et al. A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2016;101:1008–15.
Bongarzone S, Basagni F, Sementa T, Singh N, Gakpetor C, Faugeras V, et al. Development of [18F]FAMTO: a novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands. Nucl Med Biol. 2019;68–69:14–21.
Sander K, Gendron T, Cybulska KA, Sirindil F, Zhou J, Kalber TL, et al. Development of [18F]aldoview as the first highly selective aldosterone synthase PET tracer for imaging of primary hyperaldosteronism. J Med Chem. 2021;64:9321–9.
Silins I, Sundin A, Nordeman P, Jahan M, Estrada S, Monazzam A, et al. Para-chloro-2-[18F]fluoroethyl-etomidate: a promising new PET radiotracer for adrenocortical imaging. Int J Med Sci. 2021;18:2187–96.
Silins I, Sundin A, Lubberink M, O’Sullivan L, Gurnell M, Aigbirhio F, et al. First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours. Eur J Nucl Med Mol Imaging. 2023;50:398–409.
Kawaguchi N, Zhang T-T, Nakanishi T. Involvement of CXCR4 in normal and abnormal development. Cells. 2019;8:185.
Weiss ID, Jacobson O. Molecular imaging of chemokine receptor CXCR4. Theranostics. 2013;3:76–84.
Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82.
Demmer O, Gourni E, Schumacher U, Kessler H, Wester H-J. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem. 2011;6:1789–91.
Buck AK, Stolzenburg A, Hänscheid H, Schirbel A, Lückerath K, Schottelius M, et al. Chemokine receptor—directed imaging and therapy. Methods. 2017;130:63–71.
Itcho K, Oki K, Kobuke K, Yoshii Y, Ohno H, Yoneda M, et al. Aberrant G protein-receptor expression is associated with DNA methylation in aldosterone-producing adenoma. Mol Cell Endocrinol. 2018;461:100–4.
Demmer O, Dijkgraaf I, Schumacher U, Marinelli L, Cosconati S, Gourni E, et al. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J Med Chem. 2011;54:7648–62.
Herrmann K, Lapa C, Wester H-J, Schottelius M, Schiepers C, Eberlein U, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-Pentixafor. J Nucl Med. 2015;56:410–6.
Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for molecular imaging of aldosterone-producing adenoma. Hypertension. 2018;71:317–25.
Ding J, Tong A, Zhang Y, Wen J, Huo L. Intense 68Ga-Pentixafor activity in aldosterone-producing adrenal adenomas. Clin Nucl Med. 2020;45:336–9.
Ding J, Zhang Y, Wen J, Zhang H, Wang H, Luo Y, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. Eur J Nucl Med Mol Imaging. 2020;47:2656–65.
Ding J, Tong A, Zhang Y, Wen J, Zhang H, Hacker M, et al. Functional characterization of adrenocortical masses in nononcologic patients using 68Ga-pentixafor. J Nucl Med. 2022;63:368–75.
Gao Y, Ding J, Cui Y, Li T, Sun H, Zhao D, et al. Functional nodules in primary aldosteronism: identification of CXCR4 expression with 68Ga-pentixafor PET/CT. Eur Radiol. 2022;33:996–1003.
Hu J, Xu T, Shen H, Song Y, Yang J, Zhang A, et al. Accuracy of Gallium-68 pentixafor positron emission tomography-computed tomography for subtyping diagnosis of primary aldosteronism. JAMA Netw Open. 2023;6: e2255609.
Chaman Baz AH, van de Wiel E, Groenewoud H, Arntz M, Gotthardt M, Deinum J, et al. CXCR4-directed [68Ga]Ga-PentixaFor PET/CT versus adrenal vein sampling performance: a study protocol for a randomised two-step controlled diagnoStic Trial Ultimately comparing hypertenSion outcome in primary aldosteronism (CASTUS). BMJ Open. 2022;12: e060779.
Poschenrieder A, Osl T, Schottelius M, Hoffmann F, Wirtz M, Schwaiger M, et al. First 18F-labeled pentixafor-based imaging agent for PET imaging of CXCR4 expression in vivo. Tomogr Ann Arbor Mich. 2016;2:85–93.
Osl T, Schmidt A, Schwaiger M, Schottelius M, Wester H-J. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. Theranostics. 2020;10:8264–80.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ren, X., Cheng, G. & Wang, Z. Advances in the molecular imaging of primary aldosteronism. Ann Nucl Med 37, 433–441 (2023). https://doi.org/10.1007/s12149-023-01851-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-023-01851-y